ARTICLE | Discovery & Translation
Bridge Bio goes early with next-gen chemoproteomics
The Korean biotech’s collaboration with Vividion co-founders at Scripps will explore reactive chemistries beyond cysteine
February 16, 2022 8:18 PM UTC
Bridge Bio is continuing its push for early-stage assets by partnering with chemoproteomics pioneers at Scripps Research, with the goal of developing tunable covalent binders and targeted degraders.
“This research collaboration is part of how we’re building out our in-house discovery capabilities,” Bridge EVP Christopher Kim told BioCentury...